Previous close | 8.12 |
Open | 8.08 |
Bid | 7.27 x 800 |
Ask | 8.50 x 2200 |
Day's range | 7.75 - 8.14 |
52-week range | 4.81 - 17.93 |
Volume | |
Avg. volume | 626,474 |
Market cap | 370.809M |
Beta (5Y monthly) | 0.64 |
PE ratio (TTM) | N/A |
EPS (TTM) | -3.61 |
Earnings date | 23 Feb 2022 - 28 Feb 2022 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 18.67 |
DURHAM, N.C., May 25, 2022--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today announced that Raj Kannan, Chief Executive Officer, along with Peter Lang, Chief Financial Officer, and Dr. Gary Sternberg, Chief Medical Officer, will present at the Jefferies Healthcare Conference on Friday, June 10, 2022 at 10:30 a.m. Eastern Time in New York City, NY.
Aerie Pharmaceutials (AERI) doses the first patient in a phase III study on its investigational TRMP8 agonist drug for the treatment of dry eye disease.
DURHAM, N.C., May 24, 2022--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development, and commercialization of first-in-class ophthalmic therapies, today announced that the first participant has been dosed in the Phase 3 registrational "COMET-2" study to evaluate AR-15512 ophthalmic solution as a treatment for the signs and symptoms of dry eye disease (DED). COMET-2 is the first of three trials in the Phase 3 registrational program for AR-15512.